Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • GSK launches Iodex...

    GSK launches Iodex UltraGel

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-01-31T13:23:19+05:30  |  Updated On 31 Jan 2020 1:23 PM IST
    GSK launches Iodex UltraGel

    New Delhi – GSK announced the launch of Iodex UltraGel, a new age clinically proven gel-based body pain solution. Backed by science, the new variant penetrates to the root cause of pain, reduces internal swelling and gives effective relief. With this launch, GSK strengthens its presence in the topical pain relief category.

    While ordinary counter-irritant pain relief creams give burning sensation on the skin, the new Iodex UltraGel with emulgel formulation contains Diclofenac Diethylamine 1.16% w/w, that penetrates deep to the source of pain to give effective relief. The product has modern sensorials like pleasant smell, non-greasy texture and cooling sensation which makes it a convenient pain relief solution both at home and on the go.

    The launch strengthens GSK's pain relief portfolio in India making it one of the formidable players in the non-prescription space.

    Iodex UltraGel was exclusively previewed at the Indian Orthopaedic Association Annual Conference'19 (IOACON), one of the biggest orthopaedic conglomerations in South Asia. As part of the launch, the brand will be reaching out to over 5000 orthopaedics to promote the clinically proven credentials of the new product.

    Naveed Ahmed, Area Marketing Director, GSK said, "Brand Iodex has stayed relevant for over a century making it a household name that is trusted by millions. Today's changing lifestyle has resulted in an increase in pain occurrences, be it back, neck & shoulder or joint pains. We are addressing the needs of these sets of consumers by launching Iodex UltraGel, a clinically proven formulation that will offer effective pain relief, making it one of the best pain solutions available in the market. We are confident that this launch will further augment consumer trust in the brand and help strengthen our topical pain relief portfolio."

    Iodex is one of India's leading topical pain relievers. It was launched 100 years ago and has since become a household brand, selling over 4 million bottles every month.

    Iodex UltraGel is available in two packs- 15 g at Rs. 65 and 30 g at Rs. 125 and is available across all leading chemist stores pan-India.

    GSK group of companies globally owns some of the world's best-loved healthcare brands, successful in over 100 countries. These include Sensodyne, Voltaren, Theraflu, Paradontax, Panadol, Polident, Otrivin, Horlicks and Physiogel.

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok